A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Lassa Fever, Lassa Virus Infection

In brief

A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health

Key facts

Study ID
NCT04794218
Run by
International AIDS Vaccine Initiative
People needed
114
Starts
2021-06-23
Expected to finish
2024-03-01
Last updated by the study team
2024-01-18

Who can join

Age: 18 and older, up to 51. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.